Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
Sell
40
ASND Quote, Financials, Valuation and Earnings
Last price:
$159.55
Seasonality move
:
1.92%
Day range:
$160.01 - $164.81
52-week range:
$111.09 - $183.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.98x
P/B ratio:
--
Volume:
551.1K
Avg. volume:
576.3K
1-year change:
18.39%
Market cap:
$9.7B
Revenue:
$393.6M
EPS (TTM):
-$6.29
Analysts' Opinion
-
Consensus RatingAscendis Pharma AS has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $222.60, Ascendis Pharma AS has an estimated upside of 38.27% from its current price of $160.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $193.35 representing -20.1% downside risk from its current price of $160.99.
Fair Value
-
According to the consensus of 12 analysts, Ascendis Pharma AS has 38.27% upside to fair value with a price target of $222.60 per share.
ASND vs. S&P 500
-
Over the past 5 trading days, Ascendis Pharma AS has underperformed the S&P 500 by -4.62% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ascendis Pharma AS does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ascendis Pharma AS has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Ascendis Pharma AS reported revenues of $106.2M.
Earnings Growth
-
Ascendis Pharma AS has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ascendis Pharma AS reported earnings per share of -$1.66.
Enterprise value:
10.1B
EV / Invested capital:
14.16x
Price / LTM sales:
23.98x
EV / EBIT:
--
EV / Revenue:
25.58x
PEG ratio (5yr expected):
-0.47x
EV / Free cash flow:
-21.90x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$335.9M
Return On Assets:
-34.81%
Net Income Margin (TTM):
-93.27%
Return On Equity:
-880.05%
Return On Invested Capital:
-59.13%
Operating Margin:
-103.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $81.5M | $356.4M | $394M | $104.2M | $106.2M | |
| Gross Profit | $68.4M | $305.1M | $335.9M | $95.9M | $87.8M | |
| Operating Income | -$601.7M | -$392.7M | -$359.1M | -$53.4M | -$109.7M | |
| EBITDA | -$495M | -$385.5M | -$266.3M | -$50.9M | -$51.3M | |
| Diluted EPS | -$10.52 | -$9.65 | -$6.29 | -$2.50 | -$1.66 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $805.7M | $1.3B | $883.1M | $717.2M | $997.4M | |
| Total Assets | $1.1B | $1.5B | $1.1B | $866.6M | $1.1B | |
| Current Liabilities | $85.5M | $106.4M | $216.3M | $862.8M | $958.4M | |
| Total Liabilities | $190.5M | $786.2M | $871.3M | $1.1B | $1.4B | |
| Total Equity | $941.1M | $750.9M | $182.3M | -$257.2M | -$205.4M | |
| Total Debt | -- | -- | $551.1M | $722.5M | $917M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$522.8M | -$506M | -$331.4M | -$43.4M | -$90.5M | |
| Cash From Investing | $65.1M | $310.1M | $7.4M | $5.5M | -$542.4K | |
| Cash From Financing | $418.4M | $145.4M | $480.5M | -$7.4M | -$7.7M | |
| Free Cash Flow | -$538M | -$508.6M | -$333M | -$43.3M | -$90.9M | |
ASND
Sector
Market Cap
$9.7B
$34.5M
Price % of 52-Week High
87.97%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.79%
1-Year Price Total Return
18.39%
-42.08%
Beta (5-Year)
0.407
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$167.00
200-day SMA
Buy
Level
$138.94
Bollinger Bands (100)
Buy
Level
131.15 - 159.53
Chaikin Money Flow
Buy
Level
25.4M
20-day SMA
Buy
Level
$160.19
Relative Strength Index (RSI14)
Buy
Level
51.05
ADX Line
Buy
Level
18
Williams %R
Neutral
Level
-73.7848
50-day SMA
Buy
Level
$156.68
MACD (12, 26)
Buy
Level
3.77
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
18.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-4.6017)
Sell
Beneish M-Score
(Annual)
Level (-0.5381)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (5.5901)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Stock Forecast FAQ
In the current month, ASND has received 12 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ASND average analyst price target in the past 3 months is $222.60.
-
Where Will Ascendis Pharma AS Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ascendis Pharma AS share price will rise to $222.60 per share over the next 12 months.
-
What Do Analysts Say About Ascendis Pharma AS?
Analysts are divided on their view about Ascendis Pharma AS share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ascendis Pharma AS is a Sell and believe this share price will drop from its current level to $193.35.
-
What Is Ascendis Pharma AS's Price Target?
The price target for Ascendis Pharma AS over the next 1-year time period is forecast to be $222.60 according to 12 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ASND A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ascendis Pharma AS is a Buy. 12 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ASND?
You can purchase shares of Ascendis Pharma AS via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ascendis Pharma AS shares.
-
What Is The Ascendis Pharma AS Share Price Today?
Ascendis Pharma AS was last trading at $159.55 per share. This represents the most recent stock quote for Ascendis Pharma AS. Yesterday, Ascendis Pharma AS closed at $160.99 per share.
-
How To Buy Ascendis Pharma AS Stock Online?
In order to purchase Ascendis Pharma AS stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 18.42% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 7.02% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.15% over the past day.
